# A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma

> **NCT00415155** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Eli Lilly and Company** · enrollment: 60 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** LY2181308

## Key facts

- **NCT ID:** NCT00415155
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-08
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 60 (ESTIMATED)
- **Why stopped:** Trial cancelled
- **Last updated:** 2008-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00415155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00415155, "A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00415155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*